IRIS - Res&Arch Institutional Research Information System - Research & Archive

GIUSTOZZI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.622
AS - Asia 1.503
EU - Europa 1.010
SA - Sud America 267
AF - Africa 40
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.446
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.579
SG - Singapore 804
IT - Italia 230
CN - Cina 226
IE - Irlanda 222
BR - Brasile 192
RU - Federazione Russa 189
HK - Hong Kong 183
VN - Vietnam 101
DE - Germania 95
FR - Francia 69
FI - Finlandia 44
GB - Regno Unito 42
IN - India 37
SE - Svezia 28
KR - Corea 22
CA - Canada 20
AR - Argentina 19
BD - Bangladesh 18
UA - Ucraina 16
MX - Messico 15
AT - Austria 14
IQ - Iraq 14
NL - Olanda 14
TR - Turchia 14
JP - Giappone 13
VE - Venezuela 13
EC - Ecuador 11
CL - Cile 10
PL - Polonia 10
ZA - Sudafrica 10
JO - Giordania 9
MA - Marocco 9
PK - Pakistan 9
CO - Colombia 8
ES - Italia 8
PH - Filippine 8
BE - Belgio 7
ID - Indonesia 6
LT - Lituania 6
UZ - Uzbekistan 6
EG - Egitto 5
PY - Paraguay 5
CH - Svizzera 4
IL - Israele 4
KE - Kenya 4
LB - Libano 4
OM - Oman 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
MY - Malesia 3
PE - Perù 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
JM - Giamaica 2
RO - Romania 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AI - Anguilla 1
AL - Albania 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DK - Danimarca 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MM - Myanmar 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RE - Reunion 1
TJ - Tagikistan 1
Totale 4.446
Salva come PNG Salva come JPEG
Città #
Singapore 609
Chandler 236
Dublin 221
Hong Kong 183
San Jose 146
Ashburn 101
San Mateo 97
Altamura 80
Perugia 73
Santa Clara 72
Moscow 66
Boardman 60
Beijing 58
Medford 53
Lawrence 52
Princeton 52
Lauterbourg 50
Munich 42
Los Angeles 37
Wilmington 33
Des Moines 30
Redmond 29
New York 28
Andover 27
Ho Chi Minh City 27
Dong Ket 25
Seoul 22
The Dalles 21
Hanoi 20
Turku 20
São Paulo 19
Redwood City 16
Columbus 14
Helsinki 14
Nuremberg 14
Orem 11
Tokyo 11
Dallas 10
Shanghai 10
Amsterdam 9
Chicago 9
Norwalk 9
Rome 9
Saint Petersburg 9
Ancona 8
Montreal 8
Piscataway 8
Amman 7
Brussels 7
Caracas 7
Chennai 7
Denver 7
Falls Church 7
Houston 7
Warsaw 7
Baghdad 6
Falkenstein 6
Frankfurt am Main 6
Johannesburg 6
Manchester 6
Quito 6
Rio de Janeiro 6
San Paolo di Civitate 6
Stockholm 6
Brooklyn 5
Casablanca 5
Santiago 5
Seattle 5
Ann Arbor 4
Asunción 4
Atlanta 4
Belo Horizonte 4
Bexley 4
Brasília 4
Buffalo 4
Delhi 4
Guarulhos 4
Haiphong 4
Kyiv 4
Lahore 4
London 4
Mexico City 4
Mumbai 4
Nairobi 4
New Delhi 4
Poplar 4
Tashkent 4
Addis Ababa 3
Bogotá 3
Buenos Aires 3
Cairo 3
Campina Grande 3
Cebu City 3
Córdoba 3
Guangzhou 3
Guayaquil 3
Hefei 3
Jeddah 3
Juiz de Fora 3
Lima 3
Totale 3.003
Salva come PNG Salva come JPEG
Nome #
Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENo Study 125
Patients aged 90  years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study 105
Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the ‘Letter to the Editor’ from Dr. Sorigue et al 105
Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes 103
Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis 102
Non-cirrhotic Extra-Hepatic Porto-Systemic Shunt Causing Adult-Onset Encephalopathy Treated with Endovascular Closure 99
Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis 98
Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation 98
Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation 96
Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer 94
Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation 94
Safety of Anticoagulation in Patients Treated with Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation 94
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion 92
Lower dose direct oral anticoagulants and improved survival: A combined analysis in patients with established atherosclerosis 91
Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer 89
Use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life: comparison with phase III trials 88
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis 88
Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer 88
Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study 88
Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation 88
Effects of Direct Oral Anticoagulants' Nonrecommended Dose in Atrial Fibrillation: A Meta-Analysis 87
Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation 87
Beyond the guidelines: Novelties, changes and unsolved issues from the 2019 ESC guidelines on pulmonary embolism 86
Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study 85
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism 85
Lo studio EINSTEIN CHOICE 84
Risk Factors for Intracerebral Hemorrhage in Patients with Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention 84
Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy 81
Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial 81
Vitamin K and non-vitamin K antagonists oral anticoagulants for non-valvular atrial fibrillation in real-life 80
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation 78
Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study 78
Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis 77
Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians 73
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants 71
Safety of catheter ablation of atrial fibrillation in cancer survivors 70
Total parenteral nutrition-induced Wernicke's encephalopathy after oncologic gastrointestinal surgery 69
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 68
Perirectal Hematoma and Intra-Abdominal Bleeding after Stapled Hemorrhoidopexy and STARR—A Proposal for a Decision-Making Algorithm 67
Treatment of venous thromboembolism in patients with cancer: What news from clinical trials? 66
The role of computed tomography angiography 3D imaging in post-operative haemorrhage after groin mesh hernioplasty during anticoagulation therapy 65
The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction 64
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment 64
DOACs in patients with brain cancers: promising but still a long way to go 61
Ten questions on venous thromboembolism 61
Real-life use of non-vitamin K antagonist oral anticoagulants in comparison with vitamin K antagonists for non-valvular atrial fibrillation: data from a prospective cohort 60
The EINSTEIN CHOICE study 58
Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism 57
Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE 57
Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management 55
Safety and efficacy of concomitant treatment with non-vitamin K antagonist oral anticoagulants and antiseizure medications: A propensity score matching cohort study 54
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding 51
Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: A case report 49
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis 47
The possible clinical impact of a threshold left atrial diameter associated with new AF in ESUS patients 45
Patients with Atrial Fibrillation receiving NOACs: The boundary between appropriate and inappropriate dose 43
Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: A meta-analysis 42
Acute venous thromboembolism in patients with brain cancer: clinical course 41
Safety and effectiveness of oral anticoagulants in patients with atrial fibrillation and stage 4 chronic kidney disease: a real-world experience 38
Shock and diffuse ST-elevation in a patient with coronavirus disease-2019 disease 38
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence 34
Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism 22
Totale 4.588
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202134 0 0 0 0 0 0 0 0 0 8 1 25
2021/2022390 1 70 5 9 19 3 6 106 12 39 64 56
2022/2023821 54 190 9 46 58 91 0 38 296 3 27 9
2023/2024334 29 38 21 6 5 0 81 5 12 26 54 57
2024/2025884 9 67 27 62 97 61 29 52 187 62 142 89
2025/20261.838 152 122 95 242 265 162 394 98 184 124 0 0
Totale 4.588